Small Nuclear RNA-Mediated Exon 51 Skipping AAV9 Gene Therapy for the Treatment of Duchenne Muscular Dystrophy

被引：0

作者：

Markmiller, Rea Lardelli ^{[1
]}

Nachtrab, Greg ^{[1
]}

Geddes, Claire ^{[1
]}

Tadokoro, Taka ^{[1
]}

Pasha, Sheik ^{[1
]}

Knowland, Daniel ^{[1
]}

Roth, Daniela ^{[1
]}

Carreno, Alberto ^{[1
]}

Villegas, Gustavo ^{[1
]}

Sarkar, Anindita ^{[1
]}

Reid, Derek ^{[1
]}

Nguyen, Lynn ^{[1
]}

Adams, Rachel ^{[1
]}

Diago, Oscar ^{[1
]}

Vakharia, Shruti ^{[1
]}

Almaguer, Bryan ^{[1
]}

Gutierrez, Haydee ^{[1
]}

Go, Yesol ^{[1
]}

Torres, Ronald ^{[1
]}

Narayan, Nandini ^{[1
]}

Vashist, Deepti ^{[1
]}

Berlin, Aaron ^{[1
]}

Tran, Amanda ^{[1
]}

Batra, Ranjan ^{[1
]}

Leonard, John E. ^{[1
]}

机构：

[1] Locanabio, San Diego, CA USA

来源：

MOLECULAR THERAPY | 2023年 / 31卷 / 04期

关键词：

D O I：

暂无

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

1198

引用

页码：571 / 571

页数：1

共 50 条

[21] Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy
Dzierlega, Kasia
Yokota, Toshifumi
GENE THERAPY, 2020, 27 (09) : 407 - 416
[22] Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy
Kasia Dzierlega
Toshifumi Yokota
Gene Therapy, 2020, 27 : 407 - 416
[23] CRISPR-Cas9-mediated exon skipping as a cardioprotective strategy in Duchenne muscular dystrophy
Wilton-Clark, Harry
Yokota, Toshifumi
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2023, 30 : 500 - 501
[24] Systemic delivery of an AAV9 exon- skipping vector significantly improves or prevents features of Duchenne muscular dystrophy in the Dup2 mouse
Wein, Nicolas
Vetter, Tatyana A.
Vulin, Adeline
Simmons, Tabatha R.
Frair, Emma C.
Bradley, Adrienne J.
V. Gushchina, Liubov
Almeida, Camila F.
Huang, Nianyuan
Lesman, Daniel
Rajakumar, Dhanarajan
Weiss, Robert B.
Flanigan, Kevin M.
MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT, 2022, 26 : 279 - 293
[25] Becker muscular dystrophy patients with deletions around exon 51; a promising outlook for exon skipping therapy in Duchenne patients
Helderman-van den Enden, A. T. J. M.
Straathof, C. S. M.
Aartsma-Rus, A.
den Dunnen, J. T.
Verbist, B. M.
Bakker, E.
Verschuuren, J. J. G. M.
Ginjaar, H. B.
NEUROMUSCULAR DISORDERS, 2010, 20 (04) : 251 - 254
[26] Comparison of AAV8 and AAV9 microdystrophin as therapeutic vectors for the treatment of Duchenne's muscular dystrophy
Foster, Helen
Foster, Keith
Athanasopoulos, Takis
Trollet, Capucine
Dickson, George
HUMAN GENE THERAPY, 2008, 19 (10) : 1175 - 1175
[27] Eteplirsen treatment for Duchenne muscular dystrophy Exon skipping and dystrophin production
Charleston, Jay S.
Schnell, Frederick J.
Dworzak, Johannes
Donoghue, Cas
Lewis, Sarah
Chen, Lei
Young, G. David
Milici, Anthony J.
Voss, Jon
DeAlwis, Uditha
Wentworth, Bruce
Rodino-Klapac, Louise R.
Sahenk, Zarife
Frank, Diane
Mendell, Jerry R.
NEUROLOGY, 2018, 90 (24) : E2146 - E2154
[28] Adeno-Associated Virus (AAV) Mediated Dystrophin Gene Transfer Studies and Exon Skipping Strategies for Duchenne Muscular Dystrophy (DMD)
Kawecka, Klaudia
Theodoulides, Michael
Hasoglu, Yalin
Jarmin, Susan
Kymalainen, Hanna
Le-Heron, Anita
Popplewell, Linda
Malerba, Alberto
Dickson, George
Athanasopoulos, Takis
CURRENT GENE THERAPY, 2015, 15 (04) : 395 - 415
[29] RNA-Modulating Therapeutics: Personalized Exon Skipping for Duchenne Muscular Dystrophy
Van Deutekom, Judith
de Kimpe, Sjef
Ekhart, Peter
van den Akker, Hanneke
Sitsen, Ad
Janson, Anneke
de Winter, Christa
Aartsma-Rus, Annemieke
van Ommen, Gert-Jan
Verschuuren, Jan
Goemans, Nathalie
Tulinius, Mar
Platenburg, Gerard
HUMAN GENE THERAPY, 2008, 19 (10) : 1062 - 1062
[30] Characterizing Immune Responses to AAV9 in a Mouse Model of Duchenne Muscular Dystrophy
Emami, Michael R.
Young, Courtney
Ma, Feiyang
Pellegrini, Matteo
Pyle, April
Spencer, Melissa
MOLECULAR THERAPY, 2020, 28 (04) : 522 - 522

← 1 2 3 4 5 →